Sara Cabras
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sara Cabras has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Canosa
Rita Levi Montalcini Department of Neuroscience University of Turin Turin Italy
16 shared publications - Adriano Chiò
‘Rita Levi Montalcini’ Department of Neuroscience University of Torino Torino Italy
14 shared publications - Andrea Calvo
‘Rita Levi Montalcini’ Department of Neuroscience University of Torino Torino Italy
14 shared publications - Rosario Vasta
ALS Center, Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Turin, Italy
13 shared publications - Cristina Moglia
ALS Center, ‘Rita Levi Montalcini’ Department of Neuroscience, University of Turin, Turin, Italy
10 shared publications Enrico Matteoni
‘Rita Levi Montalcini’ Department of Neuroscience University of Turin Turin Italy
10 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Wiley in Annals of Neurology
Rate and Shape of Functional Decline in Amyotrophic Lateral Sclerosis Identify Clinically Distinct Amyotrophic Lateral Sclerosis Phenotypes
Objective: The ALS Functional Rating Scale–Revised decline rate compresses trajectory shape into a single number, potentially missing distinct phenotypes. We tested whether shape identifies phenotypes that rate does not distinguish, and whether post‐hoc analysis recovers a hidden ultrarapid subgroup. Methods: From the Piemonte and Valle d'Aosta register (2000–2022), we applied 2 models to 1,686 amyotrophic lateral sclerosis patients: a Gaussian mixture model (GMM; rate axis) and a latent‐class mixed model (LCMM) with cubic splines (shape axis). Concordance, prognostic performance, calibration, and clinical utility were assessed at 24 months. External validation used the Emilia‐Romagna register. Results: The rate model identified 4 classes (GMM‐Slow 31%, GMM‐Inter‐slow 46%, GMM‐Inter‐fast 17%, GMM‐Catastrophic 6%; slopes −0.44 to −3.52 points/month); the shape model 4 (LCMM‐SlowLinear 46%, LCMM‐PlateauFall 23%, LCMM‐LateDecline 15%, LCMM‐RapidEarly 16%). Concordance was modest (kappa = 0.273). Adding shape to rate changed discrimination negligibly (C‐index 0.761 vs 0.755), but separated subgroups within rate classes (within GMM‐Catastrophic, 30.1 vs 12.0 months). LCMM‐LateDecline combined moderate early decline with reduced respiratory reserve (median forced vital capacity 83.5%) and 22.7‐month median survival. The combined model gave the greatest net benefit for the composite outcome. Of 945 patients excluded for sparse sampling, 367 were ultrarapid progressors with shorter survival than LCMM‐RapidEarly; findings replicated in the Emilia‐Romagna register. Interpretation: Rate and shape describe partially overlapping aspects of the disease. LCMM‐LateDecline, with moderate early decline yet occult respiratory compromise, is clinically challenging, and the 3‐visit criterion hides over half of ultrarapid patients. Rate predicts the overall burden of progression, whereas shape predicts the timing of deterioration. ANN NEUROL 2026
- 27 October 2026
- Published by Wiley in Annals of Neurology
Open AccessRate and Shape of Functional Decline in Amyotrophic Lateral Sclerosis Identify Clinically Distinct Amyotrophic Lateral Sclerosis Phenotypes
Objective: The ALS Functional Rating Scale–Revised decline rate compresses trajectory shape into a single number, potentially missing distinct phenotypes. We tested whether shape identifies phenotypes that rate does not distinguish, and whether post‐hoc analysis recovers a hidden ultrarapid subgroup. Methods: From the Piemonte and Valle d'Aosta register (2000–2022), we applied 2 models to 1,686 amyotrophic lateral sclerosis patients: a Gaussian mixture model (GMM; rate axis) and a latent‐class mixed model (LCMM) with cubic splines (shape axis). Concordance, prognostic performance, calibration, and clinical utility were assessed at 24 months. External validation used the Emilia‐Romagna register. Results: The rate model identified 4 classes (GMM‐Slow 31%, GMM‐Inter‐slow 46%, GMM‐Inter‐fast 17%, GMM‐Catastrophic 6%; slopes −0.44 to −3.52 points/month); the shape model 4 (LCMM‐SlowLinear 46%, LCMM‐PlateauFall 23%, LCMM‐LateDecline 15%, LCMM‐RapidEarly 16%). Concordance was modest (kappa = 0.273). Adding shape to rate changed discrimination negligibly (C‐index 0.761 vs 0.755), but separated subgroups within rate classes (within GMM‐Catastrophic, 30.1 vs 12.0 months). LCMM‐LateDecline combined moderate early decline with reduced respiratory reserve (median forced vital capacity 83.5%) and 22.7‐month median survival. The combined model gave the greatest net benefit for the composite outcome. Of 945 patients excluded for sparse sampling, 367 were ultrarapid progressors with shorter survival than LCMM‐RapidEarly; findings replicated in the Emilia‐Romagna register. Interpretation: Rate and shape describe partially overlapping aspects of the disease. LCMM‐LateDecline, with moderate early decline yet occult respiratory compromise, is clinically challenging, and the 3‐visit criterion hides over half of ultrarapid patients. Rate predicts the overall burden of progression, whereas shape predicts the timing of deterioration. ANN NEUROL 2026
- Open Access
- 19 October 2026
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- p. 1-10
Factors associated with post-tracheostomy survival in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a rare neurodegenerative disease characterized by upper and lower motor neuron degeneration. It leads to progressive muscle paralysis and ultimately results i...
- 19 October 2026
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- p. 1-10
Open AccessFactors associated with post-tracheostomy survival in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a rare neurodegenerative disease characterized by upper and lower motor neuron degeneration. It leads to progressive muscle paralysis and ultimately results i...
- Open Access
- 7 October 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (10) , e70778
Recalibration of the Frontal Behavioural Inventory Cut‐Off for Behavioural Screening in Amyotrophic Lateral Sclerosis
Objective: The Frontal Behavioural Inventory (FBI) was validated in behavioural‐variant frontotemporal dementia (bvFTD) with a cut‐off of 25. We tested whether this threshold is appropriate in amyotrophic lateral sclerosis (ALS), where behavioural change is milder and partly confounded by motor pathology. Methods: We analysed 506 ALS patients with a valid FBI assessment. Behavioural impairment was defined using two complementary reference standards, to minimise dependence on any single behavioural instrument: a consensus rule (pathology on ≥ 2 of three independent instruments: Edinburgh Cognitive and Behavioural ALS Screen, Frontal Systems Behaviour Scale, Beaumont Behavioural Inventory) and Latent Class Analysis. ROC analysis identified the Youden‐optimal cut‐off; agreement was quantified by Cohen's κ ; internal validity was assessed by stratified 5‐fold cross‐validation. Total and subscale scores were analysed separately. Results: Among 345 complete‐case patients, 24.6% met criteria for behavioural impairment. The FBI total discriminated impairment well (AUC 0.855, 95% CI 0.806–0.898). The Youden‐optimal cut‐off was FBI ≥ 9 (sensitivity 0.87, specificity 0.74), whereas the legacy cut‐off of 25 showed sensitivity 0.22. Subscale recalibration yielded cut‐offs of FBI‐Apathy ≥ 7 (AUC 0.808) and FBI‐Disinhibition ≥ 4 (AUC 0.851). Conclusions: In ALS, the bvFTD‐derived threshold of 25 misses most patients with behavioural involvement. FBI ≥ 9 is a promising candidate ALS‐specific screening threshold, with scores ≥ 15 indicating a higher probability of behavioural involvement; exploratory subscale thresholds of ≥ 7 for Apathy and ≥ 4 for Disinhibition are also proposed. These cut‐offs substantially improve sensitivity while maintaining acceptable specificity, but require prospective external validation before replacing current practice.
- 7 October 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (10) , e70778
Open AccessRecalibration of the Frontal Behavioural Inventory Cut‐Off for Behavioural Screening in Amyotrophic Lateral Sclerosis
Objective: The Frontal Behavioural Inventory (FBI) was validated in behavioural‐variant frontotemporal dementia (bvFTD) with a cut‐off of 25. We tested whether this threshold is appropriate in amyotrophic lateral sclerosis (ALS), where behavioural change is milder and partly confounded by motor pathology. Methods: We analysed 506 ALS patients with a valid FBI assessment. Behavioural impairment was defined using two complementary reference standards, to minimise dependence on any single behavioural instrument: a consensus rule (pathology on ≥ 2 of three independent instruments: Edinburgh Cognitive and Behavioural ALS Screen, Frontal Systems Behaviour Scale, Beaumont Behavioural Inventory) and Latent Class Analysis. ROC analysis identified the Youden‐optimal cut‐off; agreement was quantified by Cohen's κ ; internal validity was assessed by stratified 5‐fold cross‐validation. Total and subscale scores were analysed separately. Results: Among 345 complete‐case patients, 24.6% met criteria for behavioural impairment. The FBI total discriminated impairment well (AUC 0.855, 95% CI 0.806–0.898). The Youden‐optimal cut‐off was FBI ≥ 9 (sensitivity 0.87, specificity 0.74), whereas the legacy cut‐off of 25 showed sensitivity 0.22. Subscale recalibration yielded cut‐offs of FBI‐Apathy ≥ 7 (AUC 0.808) and FBI‐Disinhibition ≥ 4 (AUC 0.851). Conclusions: In ALS, the bvFTD‐derived threshold of 25 misses most patients with behavioural involvement. FBI ≥ 9 is a promising candidate ALS‐specific screening threshold, with scores ≥ 15 indicating a higher probability of behavioural involvement; exploratory subscale thresholds of ≥ 7 for Apathy and ≥ 4 for Disinhibition are also proposed. These cut‐offs substantially improve sensitivity while maintaining acceptable specificity, but require prospective external validation before replacing current practice.
- Open Access
- 18 September 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (10) , 604
What do ALS motor phenotypes measure? A population-based decomposition of their prognostic dimensions
Background: The ALS-OPM 3.3 classification stratifies incident ALS through three axes: onset region (O), propagation time (P) and motor-neuron pattern (M). We assessed whether OPM 3.3 improves prognostic discrimination over established classifications and characterised how it decomposes their prognostic signal in a population-based cohort. Methods: In the prospective Piedmont and Aosta Valley ALS Register (2000–2022), patients were classified on the three axes; M was operationalised as M_3class (M0 balanced, M1d UMN-predominant, M2d LMN-predominant), with the PLS-spectrum M1p analysed separately. Outcome was survival (death or tracheostomy) from onset. Multivariable Cox models (O, P1(n), M_3class, age, sex) underwent bootstrap optimism-correction and fivefold cross-validation, and were compared against alternative taxonomies and clinical staging systems. Results: Amongst 2,738 non-PLS patients (2,561 events, 93.5%), median survival differed across M classes (M0 27.0, M2d 36.0, M1d 41.9 months). OPM 3.3 outperformed the bulbar/spinal dichotomy but matched the classical phenotype (optimism-corrected C-index 0.703, 95% CI 0.685–0.719 vs 0.701). In the arm-proximal cell (95.7% M2d), the O2p protective effect vanished after M adjustment (HR 0.99, 95% CI 0.79–1.24), whilst M2d retained HR 0.83 (95% CI 0.72–0.95), showing prognosis reflects motor-neuron pattern, not anatomy. Adding King’s, Milano-Torino (MiToS), or Fine’til 9 (FT9) clinical staging further improved discrimination. Conclusions: OPM 3.3 did not improve discrimination over established phenotypes but decomposed their prognostic signal into independently interpretable dimensions. Favourable prognosis of arm-proximal/flail-arm onset reflects the underlying LMN-predominant phenotype, not onset site. The motor-neuron axis is robust to the treatment of the propagation axis and independent of clinical staging.
- 18 September 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (10) , 604
Open AccessWhat do ALS motor phenotypes measure? A population-based decomposition of their prognostic dimensions
Background: The ALS-OPM 3.3 classification stratifies incident ALS through three axes: onset region (O), propagation time (P) and motor-neuron pattern (M). We assessed whether OPM 3.3 improves prognostic discrimination over established classifications and characterised how it decomposes their prognostic signal in a population-based cohort. Methods: In the prospective Piedmont and Aosta Valley ALS Register (2000–2022), patients were classified on the three axes; M was operationalised as M_3class (M0 balanced, M1d UMN-predominant, M2d LMN-predominant), with the PLS-spectrum M1p analysed separately. Outcome was survival (death or tracheostomy) from onset. Multivariable Cox models (O, P1(n), M_3class, age, sex) underwent bootstrap optimism-correction and fivefold cross-validation, and were compared against alternative taxonomies and clinical staging systems. Results: Amongst 2,738 non-PLS patients (2,561 events, 93.5%), median survival differed across M classes (M0 27.0, M2d 36.0, M1d 41.9 months). OPM 3.3 outperformed the bulbar/spinal dichotomy but matched the classical phenotype (optimism-corrected C-index 0.703, 95% CI 0.685–0.719 vs 0.701). In the arm-proximal cell (95.7% M2d), the O2p protective effect vanished after M adjustment (HR 0.99, 95% CI 0.79–1.24), whilst M2d retained HR 0.83 (95% CI 0.72–0.95), showing prognosis reflects motor-neuron pattern, not anatomy. Adding King’s, Milano-Torino (MiToS), or Fine’til 9 (FT9) clinical staging further improved discrimination. Conclusions: OPM 3.3 did not improve discrimination over established phenotypes but decomposed their prognostic signal into independently interpretable dimensions. Favourable prognosis of arm-proximal/flail-arm onset reflects the underlying LMN-predominant phenotype, not onset site. The motor-neuron axis is robust to the treatment of the propagation axis and independent of clinical staging.
- Open Access
- 15 September 2026
- Published by Elsevier in Stem Cell Research
- Vol. 96
Establishment of two iPSC lines from ALS patients carrying mutations in SQSTM1 and TBK1 genes
- 15 September 2026
- Published by Elsevier in Stem Cell Research
- Vol. 96
Open AccessEstablishment of two iPSC lines from ALS patients carrying mutations in SQSTM1 and TBK1 genes
- Open Access
- 12 August 2026
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 72 (6) , 682-693.e5
Advance Care Planning in Amyotrophic Lateral Sclerosis: A Retrospective Population-based Study
- 12 August 2026
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 72 (6) , 682-693.e5
Open AccessAdvance Care Planning in Amyotrophic Lateral Sclerosis: A Retrospective Population-based Study
- Open Access
- 31 July 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (8) , e70720
Early Cognitive and Behavioral Changes in Primary Lateral Sclerosis: A Population‐Based Study
Objective: Primary lateral sclerosis (PLS) is a rare upper motor neuron neurodegenerative disorder whose cognitive profile, particularly at early stages, remains incompletely defined. We aimed to characterize cognitive and behavioral features of PLS at diagnosis and compare them with predominant upper motor neuron amyotrophic lateral sclerosis (PUMN‐ALS) and healthy controls (HCs). Methods: Patients diagnosed with PLS between 2007 and 2021 were identified from the population‐based Piemonte and Valle d'Aosta ALS Register. Diagnoses were established according to consensus criteria, including early, probable, and definite PLS. All patients underwent comprehensive neuropsychological and behavioral assessment within 3 months of their first ALS center visit. Cognitive–behavioral status was classified using ALS–frontotemporal dementia (FTD) consensus criteria. Results: Thirty‐two PLS patients were included (mean disease duration, 25 months). Cognitive and/or behavioral impairment was identified in 29.3% of patients, most commonly affecting executive function, memory, and social cognition, including 21.1% early PLS. Compared with HCs, PLS patients showed poorer performance across several cognitive domains and higher anxiety and depression scores. Compared with matched PUMN‐ALS patients, PLS patients demonstrated slightly worse executive performance, while the overall frequency of cognitive–behavioral impairment was similar. Behavioral profiles differed qualitatively, with apathy more frequent in PUMN‐ALS. No PLS patient met criteria for frontotemporal dementia. Interpretation: Cognitive and behavioral impairments are already detectable at the time of diagnosis in a substantial proportion of patients with PLS, including early PLS, supporting the view of PLS as a multidimensional neurodegenerative disorder with early extramotor involvement.
- 31 July 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (8) , e70720
Open AccessEarly Cognitive and Behavioral Changes in Primary Lateral Sclerosis: A Population‐Based Study
Objective: Primary lateral sclerosis (PLS) is a rare upper motor neuron neurodegenerative disorder whose cognitive profile, particularly at early stages, remains incompletely defined. We aimed to characterize cognitive and behavioral features of PLS at diagnosis and compare them with predominant upper motor neuron amyotrophic lateral sclerosis (PUMN‐ALS) and healthy controls (HCs). Methods: Patients diagnosed with PLS between 2007 and 2021 were identified from the population‐based Piemonte and Valle d'Aosta ALS Register. Diagnoses were established according to consensus criteria, including early, probable, and definite PLS. All patients underwent comprehensive neuropsychological and behavioral assessment within 3 months of their first ALS center visit. Cognitive–behavioral status was classified using ALS–frontotemporal dementia (FTD) consensus criteria. Results: Thirty‐two PLS patients were included (mean disease duration, 25 months). Cognitive and/or behavioral impairment was identified in 29.3% of patients, most commonly affecting executive function, memory, and social cognition, including 21.1% early PLS. Compared with HCs, PLS patients showed poorer performance across several cognitive domains and higher anxiety and depression scores. Compared with matched PUMN‐ALS patients, PLS patients demonstrated slightly worse executive performance, while the overall frequency of cognitive–behavioral impairment was similar. Behavioral profiles differed qualitatively, with apathy more frequent in PUMN‐ALS. No PLS patient met criteria for frontotemporal dementia. Interpretation: Cognitive and behavioral impairments are already detectable at the time of diagnosis in a substantial proportion of patients with PLS, including early PLS, supporting the view of PLS as a multidimensional neurodegenerative disorder with early extramotor involvement.
- Open Access
- 30 July 2026
- Published by Wiley in Annals of Neurology
- Vol. 100 (5) , 934-947
Toward a Behavioral Reserve Model in Amyotrophic Lateral Sclerosis
Objective: Behavioral impairment is common in amyotrophic lateral sclerosis (ALS) and strongly affects autonomy, caregiver burden, and outcomes, yet predictors of vulnerability remain unclear. We investigated whether premorbid regulatory traits and socio‐educational exposures are associated with behavioral phenotypes in ALS within a behavioral reserve framework. Methods: We analyzed 965 consecutively assessed patients with ALS from a prospective tertiary‐center cohort. Behavioral impairment was measured using the Frontal Systems Behavior Scale (FrSBe; family‐rated before and after onset) and, in a subset (n = 633), the Edinburgh Cognitive and Behavioural ALS Screen–Carer Interview (ECAS‐CI). Theory‐driven hierarchical logistic regression models tested associations between behavioral outcomes and premorbid behavioral regulation, education, occupation, and a Social Interaction Index, including interaction effects. Prespecified sensitivity analyses addressed potential bias in premorbid estimates. Results: Premorbid behavioral regulation showed the strongest associations with behavioral impairment across all FrSBe models. Higher combined educational attainment and social exposure were associated with lower odds of impairment, with a significant interaction across multiple behavioral domains. These patterns persisted in restricted sensitivity analyses. Reserve proxies were not significantly associated with ECAS‐CI total impairment, although domain‐specific effects were observed. Interpretation: These findings provide empirical support for a behavioral reserve framework in ALS, in which premorbid regulatory traits and socio‐educational exposures are associated with behavioral vulnerability. Although causal inference is limited, reserve‐related factors may contribute to non‐motor heterogeneity in ALS and may inform future approaches to early behavioral risk stratification. ANN NEUROL 2026;100:934–947
- 30 July 2026
- Published by Wiley in Annals of Neurology
- Vol. 100 (5) , 934-947
Open AccessToward a Behavioral Reserve Model in Amyotrophic Lateral Sclerosis
Objective: Behavioral impairment is common in amyotrophic lateral sclerosis (ALS) and strongly affects autonomy, caregiver burden, and outcomes, yet predictors of vulnerability remain unclear. We investigated whether premorbid regulatory traits and socio‐educational exposures are associated with behavioral phenotypes in ALS within a behavioral reserve framework. Methods: We analyzed 965 consecutively assessed patients with ALS from a prospective tertiary‐center cohort. Behavioral impairment was measured using the Frontal Systems Behavior Scale (FrSBe; family‐rated before and after onset) and, in a subset (n = 633), the Edinburgh Cognitive and Behavioural ALS Screen–Carer Interview (ECAS‐CI). Theory‐driven hierarchical logistic regression models tested associations between behavioral outcomes and premorbid behavioral regulation, education, occupation, and a Social Interaction Index, including interaction effects. Prespecified sensitivity analyses addressed potential bias in premorbid estimates. Results: Premorbid behavioral regulation showed the strongest associations with behavioral impairment across all FrSBe models. Higher combined educational attainment and social exposure were associated with lower odds of impairment, with a significant interaction across multiple behavioral domains. These patterns persisted in restricted sensitivity analyses. Reserve proxies were not significantly associated with ECAS‐CI total impairment, although domain‐specific effects were observed. Interpretation: These findings provide empirical support for a behavioral reserve framework in ALS, in which premorbid regulatory traits and socio‐educational exposures are associated with behavioral vulnerability. Although causal inference is limited, reserve‐related factors may contribute to non‐motor heterogeneity in ALS and may inform future approaches to early behavioral risk stratification. ANN NEUROL 2026;100:934–947
- Open Access
- 28 November 2025
- Published by Wiley in Annals of Neurology
- Vol. 99 (3) , 606-613
The Epidemiology of Primary Lateral Sclerosis: Results from a Population‐Based Cohort
Objective: In this population‐based study, we described the epidemiology of primary lateral sclerosis (PLS) in northern Italy and compared the clinical characteristics of patients with PLS to those with predominant upper motor neuron (PUMN) involvement and classic amyotrophic lateral sclerosis (ALS). Methods: Patients from the PARALS registry diagnosed with probable or definite PLS between 2007 and 2021 were included. Crude annual incidence rates were calculated, along with age‐ and sex‐specific rates. A survival analysis was performed to identify prognostic factors at diagnosis. Covariates included sex, age at onset, site of onset, diagnostic delay, forced vital capacity (FVC), change in ALS Functional Rating Scale (ΔFRS), and change in body mass index (ΔBMI). Results: A total of 57 PLS patients (2.7%) were included, with a crude incidence rate of 0.084 per 100,000 person‐years. Compared to PUMN and classic ALS, PLS patients were younger (median onset age 63.5 years, interquartile range [IQR] 54.9–70.4) and predominantly female (male‐to‐female ratio 0.58). Bulbar onset occurred in 11 cases (19.3%), all of whom later developed spinal symptoms. At censoring, 38 patients (66.7%) were still alive (median survival 8.3 years, IQR 5.7–12.3), corresponding to a point prevalence of 0.89 per 100,000. Survival was significantly associated with age at onset (hazard ratio [HR] 1.17, 95% confidence interval [CI]: 1.05–1.33, p = 0.001), male sex (HR 4.41, 95% CI: 1.24–15.6, p = 0.02), and FVC at diagnosis (HR 0.95, 95% CI: 0.93–0.98, p = 0.006). Interpretation: PLS was confirmed to be rarer than other ALS phenotypes. Patients had a higher age at onset than previously reported and a female predominance. Sex, age at onset, and respiratory function were key prognostic factors. ANN NEUROL 2026;99:606–613
- 28 November 2025
- Published by Wiley in Annals of Neurology
- Vol. 99 (3) , 606-613
Open AccessThe Epidemiology of Primary Lateral Sclerosis: Results from a Population‐Based Cohort
Objective: In this population‐based study, we described the epidemiology of primary lateral sclerosis (PLS) in northern Italy and compared the clinical characteristics of patients with PLS to those with predominant upper motor neuron (PUMN) involvement and classic amyotrophic lateral sclerosis (ALS). Methods: Patients from the PARALS registry diagnosed with probable or definite PLS between 2007 and 2021 were included. Crude annual incidence rates were calculated, along with age‐ and sex‐specific rates. A survival analysis was performed to identify prognostic factors at diagnosis. Covariates included sex, age at onset, site of onset, diagnostic delay, forced vital capacity (FVC), change in ALS Functional Rating Scale (ΔFRS), and change in body mass index (ΔBMI). Results: A total of 57 PLS patients (2.7%) were included, with a crude incidence rate of 0.084 per 100,000 person‐years. Compared to PUMN and classic ALS, PLS patients were younger (median onset age 63.5 years, interquartile range [IQR] 54.9–70.4) and predominantly female (male‐to‐female ratio 0.58). Bulbar onset occurred in 11 cases (19.3%), all of whom later developed spinal symptoms. At censoring, 38 patients (66.7%) were still alive (median survival 8.3 years, IQR 5.7–12.3), corresponding to a point prevalence of 0.89 per 100,000. Survival was significantly associated with age at onset (hazard ratio [HR] 1.17, 95% confidence interval [CI]: 1.05–1.33, p = 0.001), male sex (HR 4.41, 95% CI: 1.24–15.6, p = 0.02), and FVC at diagnosis (HR 0.95, 95% CI: 0.93–0.98, p = 0.006). Interpretation: PLS was confirmed to be rarer than other ALS phenotypes. Patients had a higher age at onset than previously reported and a female predominance. Sex, age at onset, and respiratory function were key prognostic factors. ANN NEUROL 2026;99:606–613
- Open Access
- 17 November 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (12) , 766
Role of 2-[18F]FDG-PET as a biomarker of upper motor neuron involvement in amyotrophic lateral sclerosis
Introduction: Amyotrophic Lateral Sclerosis (ALS) affects upper (UMN) and lower (LMN) motor neurons. ALS diagnosis is challenging, especially in predominant LMN phenotypes. Electromyography can disclose LMN damage, while UMN involvement is detectable by clinical examination, with possible support of magnetic resonance imaging (MRI) and transcranial magnetic stimulation. Our aim was to investigate the role of 2-[ 18 F]FDG-PET as an UMN biomarker in ALS. Methods: In our cross-sectional study, we created an UMN burden score. Performing a multiple regression analysis in SPM12, we evaluated the relationship between UMNBS and brain metabolism. We split ALS cohort based on the UMN burden score median value (group A—under median, group B—above median). We ran a full factorial analysis including group A and B and healthy controls, followed by group comparisons. Results: We included 118 ALS patients (group A and B, N = 59), with a median UMN burden score of 9.50 and a left lateralization of UMN signs. We found a negative correlation between motor cortex metabolism and UMN burden score. Comparing each ALS group with healthy controls, we found relative hypometabolism in the left frontal lobe and relative bilateral, right-prevalent hypermetabolism of cerebellum and corticospinal tracts. The relative hypermetabolism in corticospinal tracts was more evident in the group with low UMN signs. Conclusions: Motor cortex metabolism reflects UMN burden. Corticospinal tracts’ metabolic changes could provide information about UMN involvement even in patients with predominant LMN phenotype, suggesting a possible role of brain 2-[ 18 F]FDG-PET as an UMN biomarker in ALS patients.
- 17 November 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (12) , 766
Open AccessRole of 2-[18F]FDG-PET as a biomarker of upper motor neuron involvement in amyotrophic lateral sclerosis
Introduction: Amyotrophic Lateral Sclerosis (ALS) affects upper (UMN) and lower (LMN) motor neurons. ALS diagnosis is challenging, especially in predominant LMN phenotypes. Electromyography can disclose LMN damage, while UMN involvement is detectable by clinical examination, with possible support of magnetic resonance imaging (MRI) and transcranial magnetic stimulation. Our aim was to investigate the role of 2-[ 18 F]FDG-PET as an UMN biomarker in ALS. Methods: In our cross-sectional study, we created an UMN burden score. Performing a multiple regression analysis in SPM12, we evaluated the relationship between UMNBS and brain metabolism. We split ALS cohort based on the UMN burden score median value (group A—under median, group B—above median). We ran a full factorial analysis including group A and B and healthy controls, followed by group comparisons. Results: We included 118 ALS patients (group A and B, N = 59), with a median UMN burden score of 9.50 and a left lateralization of UMN signs. We found a negative correlation between motor cortex metabolism and UMN burden score. Comparing each ALS group with healthy controls, we found relative hypometabolism in the left frontal lobe and relative bilateral, right-prevalent hypermetabolism of cerebellum and corticospinal tracts. The relative hypermetabolism in corticospinal tracts was more evident in the group with low UMN signs. Conclusions: Motor cortex metabolism reflects UMN burden. Corticospinal tracts’ metabolic changes could provide information about UMN involvement even in patients with predominant LMN phenotype, suggesting a possible role of brain 2-[ 18 F]FDG-PET as an UMN biomarker in ALS patients.